544719-a220485c-3ee8-40bf-b860-c465f22f4262
Position
President and Head of Research and Development
Location
London Colorado UNITED STATES
Bio
As president at Spark Therapeutics, Dr. Kathy High has led the development and regulatory approval of the first gene therapy for a genetic disease in the United States. Spark has shown human proof-of-concept of its leading gene therapy platform in both the retina and the liver, and has received breakthrough therapy designations for three different therapeutics across two different tissue targets, the eye and the liver. In addition to her operational role, Kathy serves as a member of the Board of Directors of Spark. Kathy was a long-time member of the faculty at the University of Pennsylvania and of the medical staff at CHOP, where she was also an Investigator of the Howard Hughes Medical Institute. She served a five-year term on the FDA Advisory Committee on Cell, Tissue and Gene Therapies and is a past president of the American Society of Gene & Cell Therapy (ASGCT). She received her A.B. in chemistry from Harvard University, an M.D. from the University of North Carolina School of Medicine, a business certification from the University of North Carolina Business School Management Institute for Hospital Administrators and an M.A. from the University of Pennsylvania.
Interests
None yet.